Targeting the Root of Brain Cancer
Curtana Pharmaceuticals is advancing a novel, dual-action therapy designed to halt recurrence by eradicating cancer stem cells and reversing tumor-driven immune suppression.
A Clinical-Stage Pioneer in Neuro-Oncology
At Curtana Pharmaceuticals, we are driven by an urgent mission to develop life-changing therapies for patients facing the most devastating central nervous system (CNS) malignancies. Standard treatments often leave behind resilient cancer stem cells – the true root of disease recurrence. Our lead investigational therapy, CT-179, is a potent, orally available, CNS-penetrant small-molecule inhibitor targeting OLIG2, a master transcription factor. By dismantling tumor architecture at its source and reawakening the body’s innate defenses, we are committed to changing the treatment paradigm.
Lead Program
Recurrent GBM (Monotherapy)
Target First Patient: Q2 2026
Preclinical
IND-Enabling
Phase 1
Latest News
Curtana Adds Industry Luminaries to Scientific Advisory Board
November 26, 2013 – Curtana Pharmaceuticals has added Brent A. Reynolds, Ph.D. and Jeremy Rich, M.D. to its scientific advisory board, joining Santosh Kesari, M.D., Ph.D. and Wolf Wrasidlo, Ph.D.
American Brain Tumor Association-Funded Research Spurs Development of New Treatments
November 20, 2013
Curtana Signs Exclusive Worldwide License Agreement
September 23, 2013 – Curtana Pharmaceuticals has finalized an exclusive worldwide license agreement with the University of California, San Diego to develop novel first-in-class, small molecule therapeutics targeting cancer stem cells for the treatment of glioblastoma (GBM) and other cancers.